Experimental drug helps patients lose nearly a quarter of body weight in early trials
Print Close
By Melissa Rudy
Published June 23, 2025
An experimental weight-loss medication was shown to help people lose nearly 25% of their body weight in early-stage 1a/2b trials.
The drug, amycretin — developed by Novo Nordisk — works by replicating two hunger hormones — amylin, which regulates appetite and creates a feeling of fullness, and glucagon-like peptide 1 (GLP-1), the same hormone that is used in Ozempic and Wegovy to suppress appetite and boost insulin secretion.
"Amycretin is the first treatment to harness the two distinct biological pathways stimulated by amylin and GLP-1 in a single molecule," Martin Holst Lange, executive vice president and head of development at Novo Nordisk, previously said in a statement sent to Fox News Digital.
GRANDFATHER'S SIMPLE CHANGES REVERSED PRE-DIABETES DIAGNOSIS THAT LEFT HIM 'PETRIFIED'
In the study, which included 125 overweight or obese adults, participants who received weekly injections of amycretin lost more weight than those who took a placebo, according to a press release from Novo Nordisk.
Those who got the highest doses (up to 60 mg) lost up to 24.3% pounds after 36 weeks, compared to just 1.1% for the placebo group, per the release.
A previous phase 1 trial of the oral (pill) version of amycretin also showed that treatment was "safe and tolerable," with an "observed reduction in body weight" compared to placebo, the company stated.
Taking the pill once a day led to around 10% weight loss, and those who doubled the dose lost 13%.
YOUR DNA COULD BE STOPPING YOU FROM LOSING WEIGHT, NEW STUDY SUGGESTS
Another benefit the researchers highlighted is that people taking amycretin did not appear to hit a "weight-loss plateau," continuing to shed pounds as long as they took it.
"The lack of weight loss plateauing indicates the possibility of achieving further weight reductions with extended treatment," Agnes Gasoirek, a senior clinical pharmacology specialist at Novo Nordisk, wrote in the phase 1 study findings.
Novo Nordisk presented the latest findings at the American Diabetes Association in Chicago on June 22; they were also published in the medical journal Lancet.
"We are pleased with the promising results of amycretin and the feedback from regulatory authorities and are excited to advance both subcutaneous and oral versions of this molecule into phase 3 development for weight management," said Martin Holst Lange, executive vice president for Development at Novo Nordisk, in the release.
"Amycretin is the first treatment to harness the two distinct biological pathways stimulated by amylin and GLP-1 in a single molecule."
"These results reflect our robust pipeline in obesity, [and] our focus on progressing scientific innovation and expanding the range of options available to patients and healthcare professionals."
The most common side effects of amycretin, similar to other GLP-1s, were gastrointestinal symptoms — primarily nausea, vomiting and decreased appetite.
CLICK HERE TO GET THE FOX NEWS APP
Adverse events were "mild to moderate" in severity, according to researchers. More frequent doses resulted in greater side effects.
It's important to monitor these side effects closely, experts advise, as GI issues are common among patients with obesity.
"While the initial weight-loss outcomes are indeed encouraging, further studies are needed to ensure that the therapeutic benefits consistently outweigh the potential risks, especially with long-term administration," Dr. Christine Ren-Fielding, director and chief of bariatric surgery at the NYU Langone Weight Management Program, previously told Fox News Digital.
CLICK HERE TO SIGN UP FOR OUR HEALTH NEWSLETTER
While GLP-1-based drugs — including this new experimental pill — may show promising results, Ren-Fielding, who was not involved in the study, emphasized that they're "not a cure-all for obesity."
"Obesity is a chronic, multifactorial disease that requires a comprehensive, long-term approach," she said at the time.
For more Health articles, visit www.foxnews.com/health
"Pharmacological treatments can play a significant role in managing the condition, but they are often most effective when combined with other interventions."
Next, Novo Nordisk plans to prepare for phase 3 trials of the medication, in both oral and injectable forms, for the management of obesity. Print Close
URL
https://www.foxnews.com/health/experimental-drug-helps-patients-lose-nearly-quarter-body-weight-early-trials
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Medscape
23 minutes ago
- Medscape
Training Reduces Clinicians' Obesity Bias, Improves Practice
Many healthcare providers (HCPs) harbor bias against people with excess weight or obesity, and that stigmatization can negatively affect patient care. Now, an innovative two-endpoint continuing medical education (CME) initiative has shown that clinicians can change when brought face to face with their negative attitudes and less than optimal referral behaviors regarding patients with obesity. Amanda Velazquez, MD Reporting in the Journal of General Internal Medicine, researchers led by Amanda Velazquez, MD, of the Center for Weight Management and Metabolic Health and the Jim and Eleanor Randall Department of Surgery at Cedars-Sinai Medical Center in Los Angeles, found a 4-hour CME program, conducted in April 2021, significantly reduced HCPs' self-reported negative stereotypes compared with baseline. Self-reported empathy and confidence in caring for patients with obesity significantly increased immediately post intervention and endured at 4- and 12-month follow-up. Additionally, the 4-hour symposium led to objectively improved diagnosis and referral to obesity care for patients treated across different specialties. 'There is considerable gap in the education of healthcare professionals about obesity,' Velazquez told Medscape Medical News , adding that established data have confirmed the existence of anti-weight bias among HCPs. 'Our study was unique in that it had a broad target group and invited professionals across all specialties from plastic surgeons and Ob/Gyns to nurses and emergency medical technicians. Our goal was to move the needle toward greater comfort in referring their patients to appropriate obesity management.' She noted that excessive weight exacerbates many conditions treated outside of obesity medicine, such as psoriasis, cardiometabolic disease, and impaired fertility. The Intervention Conducted at a single site in the Kaiser Permanente Southern California healthcare system, the symposium invited a diverse population of 472 eligible HCPs. Weight Bias: Weight bias was assessed by a 16-item questionnaire originally developed for medical students by Robert F. K ushner and colleagues, designed to assess negative prejudicial beliefs about patients with obesity. This measure captured three types of weight bias: negative obesity stereotypes (eg, 'Individuals with obesity have themselves to blame'); empathy for patients (eg, 'People with obesity feel stigmatized by the medical profession'); and confidence in clinical interaction with patients with obesity (eg, 'I feel comfortable talking to people about their weight'). As a result of the program, negative obesity stereotypes among attendees, according to the post-program questionnaire, were significantly reduced over baseline levels (2.81 ± 0.47 vs 2.50 ± 0.46; P < .001), while both their empathy (3.33 ± 0.64 vs 3.47 ± 0.63; P = .006) and confidence (3.10 ± 0.86 vs 3.85 ± 0.79; P < .001) significantly increased. Practice Patterns: Behavioral outcomes of interest, according to electronic medical records, were participants' objective practice changes regarding obesity diagnosis and referrals to healthy lifestyle programs, obesity medicine, and bariatric surgery. Comparative analyses were done for 218 attendees and 89 nonparticipants. After adjustment for years in practice, race/ethnicity, gender, profession type, practice type, and panel size, HCPs who attended the program had significantly increased odds of obesity diagnosis and obesity-related referrals in the 12 months following the intervention vs those not attending. Specifically, compared with nonattendees, participants had increased odds of changes across several measures. Diagnosing obesity: odds ratio [OR], 1.60; (95% CI,1.54-1.66); referring patients to healthy lifestyle programs: OR, 1.27 (95% CI, 1.19-1.36); and referrals to an obesity medicine specialty clinic: OR, 1.87 (95% CI, 1.63-2.14). For patients with a BMI ≥ 35, the post-intervention OR for referral to bariatric surgery was 2.12 (95% CI, 1.70-2.67) in the 12 months following the intervention. The comparison group's odds either decreased or did not change. As to participation by profession type, physicians were the most likely to attend, with physicians from family medicine, internal medicine, and obstetrics/gynecology more likely to participate than those from orthopedics and ophthalmology. While Velazquez was not surprised by the level of anti-weight bias the symposium revealed, she was not prepared for the magnitude of objective change it effected in practice patterns. 'The increase in the number of referrals to obesity care was so overwhelming, we had to change the BMI eligibility criterion to handle the influx,' she said. With referrals to the obesity clinic doubling, the threshold for new referrals was raised from BMI ≥ 30 to BMI ≥ 35 to address the overwhelming demand. Leslie Heinberg, PhD Offering a nonparticipant's perspective on the intervention, Leslie Heinberg, PhD, a professor of medicine and vice chair for psychology in the Department of Psychiatry and Psychology at the Cleveland Clinic in Cleveland, called it 'an interesting and comprehensive study that goes beyond previous work in attitudinal change to look at change in actual practice behavior around obesity.' She was not surprised at the shift in attitude immediately after the symposium. 'We all know the right answers to give, but the change in attitudes persisted long after the intervention,' In her practice, patients often report experiencing weight stigma during interaction with their HCPs. 'But healthcare should be sensitive to patients across the entire weight spectrum.' Heinberg noted HCPs typically get little or no training in obesity issues, including the psychological aspects of this complex multifactorial condition. 'They might get one lecture during training, but 40% of the patients they treat will have obesity,' she said. Training is needed in how to talk to patients about excess weight. Her institution requires all new hires in any clinical capacity to have on-boarding training in obesity bias, with a yearly refresher course as well. Carolynn Francavilla, MD, an obesity medicine specialist and owner of Green Mountain Partners for Health in Lakewood, Colorado, also applauded the study. 'As someone who dedicates a significant amount of my time to developing CME and educating clinicians, I find it very encouraging that this study was able to demonstrate both reduced weight bias and improved referrals for care,' she told Medscape Medical News. 'While most physicians are now aware of treatment options, many do not understand the chronic nature of the disease and many still believe that willpower is enough to treat obesity.' The authors concluded that a focused CME intervention aimed at mitigating HCPs' weight bias and behavior can lead to improved diagnosis and referral to the full range of current options in obesity care. 'We're hoping to apply the intervention in other groups to see if it has the same positive impact on practice,' Velazquez said. 'But it will need some updating since the original interventions was conducted in 2021 before the explosion of GLP-1 therapy.' Future research should focus on integrating obesity pharmacotherapy into the CME content and further examining practice behaviors. 'In addition to a randomized trial of the intervention, future research should also assess longitudinal practice changes beyond 1 year, the authors wrote.
Yahoo
24 minutes ago
- Yahoo
SpaceX sets new date for private Axiom-4 astronaut launch to the International Space Station
When you buy through links on our articles, Future and its syndication partners may earn a commission. The crew of Houston-based Axiom Space's next launch to the space station is back on the board. Axiom's fourth astronaut mission (Ax-4) to the International Space Station (ISS) has a new launch date. The crew of four will liftoff aboard a SpaceX Crew Dragon spacecraft atop a Falcon 9 rocket no earlier than June 25, NASA announced Monday evening (June 23). Liftoff is scheduled for 2:31 a.m. EDT (0631 GMT) from Launch Complex-39A, at NASA's Kennedy Space Center, in Florida.. The launch had been indefinitely delayed last week due to a leak detected aboard the ISS. No update was given about that leak in NASA's announcement of the new launch date. The leak in the station's Zvezda module isn't new, but a change in the pressure data that measures the leak's severity prompted NASA and Axiom to postpone the Ax-4 launch until safety could be assured. The Ax-4 crew consists of former NASA astronaut and Axiom's director of human spaceflight Peggy Whitson. Whitson will serve as mission commander to Shubhanshu Shukla of India, Sławosz Uznański-Wiśniewski from Poland, and Tibor Kapu, from Hungary. All three will be the first astronauts from their respecitve nations to launch on a mission to the ISS. Related stories: — Axiom Space: Building the off-Earth economy — International Space Station: Everything you need to know about the orbital laboratory — Top 'safety risk' for the ISS is a leak that has been ongoing for 5 years, NASA audit finds The mission is expected to last two weeks. While aboard the orbiting lab, the Ax-4 crew will conduct more science experiments and STEM (science, technology, engineering and math) outreach events than any previous Axiom mission — more than 60 in total. If all stays on schedule with Wednesday's early morning launch, the crew's Dragon spacecraft is scheduled to dock with the ISS at approximately 7:00 a.m. EDT (1100 GMT) Thursday, June 26. A livestream of the launch and rendezvous will be lived stream on
Business Wire
33 minutes ago
- Business Wire
Simple Online Healthcare launches in Denmark as revenue triples
GLASGOW, Scotland--(BUSINESS WIRE)-- Simple Online Healthcare has launched in Denmark after tripling its revenue. Headquartered in Glasgow, Simple Online is one of the UK's fastest-growing healthcare groups, offering scalable, regulated digital clinics across the UK, Germany, and Australia. In the UK, it operates as Simple Online Pharmacy. Led by CEO and Co-founder Addy Mohammed, Simple Online Healthcare reported revenue of £66 million in the year to 28th February 2025 [2024: £20.6m], and marked its 10-year anniversary in April with record monthly revenue of £10 million. Addy Mohammed said: 'We're proud of how far we've come in our first ten years, and we think it's notable that we've remained fully self-funded during that time. Denmark represents our third international market, and we are planning further expansion over the next twelve months.' CFO Michael Hope said: 'We've scaled rapidly in recent years, investing across geography, supply chain, technology, and talent. Financial discipline and patient retention are underpinning our growth, allowing us to invest in new markets and our digital platform, creating an improved patient experience, differentiation, and operational efficiencies.' Addy Mohammed co-founded Simple Online Healthcare alongside university friend Karim Nassar, who is Simple Online's Chief Growth Officer, in 2015, building on their experience of owning and operating community pharmacies across Scotland to offer consumers a convenient patient-first pharmacy service with medications delivered direct to their door. The company has a headcount of 130, and plans to make additional hires this year. Simple Online was one of the first providers of weight loss medications in the UK. The business has invested significantly in its weight management programme and is one of the leading providers of GLP-1 medications Wegovy and Mounjaro, which are prescribed alongside comprehensive holistic weight management support. 'We know global healthcare systems are struggling,' says Mohammed, 'with the top issues being long waiting times, insufficient staff, and cost of treatments. We are using technology to give patients quick and discrete access to the care they need, at a much lower cost than traditional healthcare models. Combining technology with a multi-disciplinary team of health professionals, we can provide the personalised level of care you'd receive in a community pharmacy.' Simple Online has invested over £2 million into technology and systems during 2025, with Mohammed commenting: 'Digital healthcare is evolving rapidly, and we're continuing to invest in technology to enhance the patient journey and deliver best-in-class care.' 'Our vision is to make healthcare affordable and accessible,' says Mohammed. 'We support our patients with the personalised tools and knowledge to make long-term lifestyle changes.' The global online pharmacy market is valued at almost £100 billion in 2025, and is forecast to grow to around £400 billion by 2033. Simple Online's board includes former Skyscanner CFO Shane Corstorphine, and the company is set to further strengthen its executive leadership team this year.
